In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.

Sandborn, W., Gasink, C., Gao, L., Blank, M., Johanns, J., Guzzo, C., et al. (2012). Ustekinumab induction and maintenance therapy in refractory Crohn's disease. NEW ENGLAND JOURNAL OF MEDICINE, 367(16), 1519-1528 [10.1056/NEJMoa1203572].

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

Biancone L
2012

Abstract

In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/12 - Gastroenterologia
English
Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Crohn Disease; Double-Blind Method; Drug Resistance; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Remission Induction; Severity of Illness Index; Tumor Necrosis Factors; Ustekinumab
Sandborn, W., Gasink, C., Gao, L., Blank, M., Johanns, J., Guzzo, C., et al. (2012). Ustekinumab induction and maintenance therapy in refractory Crohn's disease. NEW ENGLAND JOURNAL OF MEDICINE, 367(16), 1519-1528 [10.1056/NEJMoa1203572].
Sandborn, W; Gasink, C; Gao, L; Blank, M; Johanns, J; Guzzo, C; Sands, B; Hanauer, S; Targan, S; Rutgeerts, P; Ghosh, S; De Villiers, W; Panaccione, R; Greenberg, G; Schreiber, S; Lichtiger, S; Feagan, B; CERTIFI Study, G; Biancone, L
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/155347
Citazioni
  • ???jsp.display-item.citation.pmc??? 289
  • Scopus 773
  • ???jsp.display-item.citation.isi??? ND
social impact